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ABSTRACT
The literature about possible cardiovascular consequences of diagnostic inertia in
diabetes is scarce. We examined the influence of undetected high fasting blood
glucose (FBG) levels on the cardiovascular risk and poor control of cardiovascular
risk factors in hypertensive or obese patients, with no previous diagnosis of diabetes
mellitus (i.e., diagnostic inertia). A cross-sectional study during a preventive pro-
gram in a Spanish region was performed in 2003–2004. The participants were aged
≥40 years and did not have diabetes but were hypertensive (n = 5,347) or obese
(n = 7,833). The outcomes were high cardiovascular risk (SCORE ≥ 5%), poor
control of the blood pressure (≥ 140/90 mmHg) and class II obesity. The relationship
was examined between FBG and the main parameters, calculating the adjusted odd
ratios with multivariate models. Higher values of FBG were associated with all the
outcomes. A more proactive attitude towards the diagnosis of diabetes mellitus in the
hypertensive and obese population should be adopted.
Subjects Diabetes and Endocrinology, Epidemiology, Nutrition, Public Health
Keywords Diabetes mellitus, Hypertension, Delayed diagnosis, Obesity, Physician’s practice
patterns, Primary health care
INTRODUCTION
Cardiovascular diseases (CVD) are the leading cause of mortality in the world
(WHO, 2011). Diabetes, along with hypertension, dyslipidaemia, obesity and smoking,
is one of the main risk factors for CVD (D’Agostino Sr et al., 2008). Moreover, these risk
factors are associated with each other; for instance, the chronic hyperglycaemia produced
by diabetes is associated with high blood pressure (BP) and obesity (Expert Committee on
the Diagnosis and Classification of Diabetes Mellitus, 2003).
Clinical inertia has been defined as failure by the health care provider to initiate or
intensify the treatment when this is in fact indicated (Phillips et al., 2001). A very recent
systematic review (Lebeau et al., 2014) determined that this concept has been adapted
to making mistakes in the diagnosis of a disorder (rather than its treatment), and is
known as diagnostic inertia. This diagnostic inertia has already been assessed in both
hypertension and in dyslipidaemia, determining both its prevalence and its association
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with a personal history of cardiovascular risk factors (CVRF) in the patients studied
(Gil-Guille´n et al., 2010; Palazo´n-Bru et al., 2014). Sepehri et al. (2014) assessed the relation
between inertia (defined as lack of advice about losing weight in obese patients) and the
cardiovascular risk, measured with a probabilistic function. However, we have found
no study examining the possible cardiovascular consequences of diagnostic inertia in
diabetes. This concept is of great importance, as an early diagnosis is more likely to result
in fewer future complications of CVD (D’Agostino Sr et al., 2008). Accordingly, we carried
out a study analysing patients without a diagnosis of diabetes but with a diagnosis of
hypertension or obesity to determine the existence or otherwise of an association between
the lack of detection of high fasting basal plasma glucose (FBG) concentrations and a
greater cardiovascular risk; i.e., assessing whether diagnostic inertia in diabetes mellitus
is resulting in situations of high cardiovascular risk. Thus, the results provided here are
novel and could show the need to evaluate measures to improve the diagnosis of diabetes
in hypertensive and obese patients who attend the health centre. We hypothesised that
diagnostic inertia is not associated with long-term cardiovascular consequences.
MATERIALS & METHODS
Setting
The Valencian Community is a Mediterranean region in eastern Spain with a population
(January 2004) of 4,518,126 inhabitants. Primary health care is provided in health centres,
has a universal coverage and has no cost for patients. The prevalence of diabetes is high
and it is strongly associated with other known risk factors. Moreover, a large proportion of
persons are not diagnosed, although recently screening for diabetes has greatly increased
(Generalitat Valenciana: Conselleria de Sanitat, 2010a).
In this Community, at the end of 2003, a preventive activities program addressed to all
persons aged 40 years or over was started. Each person was invited to participate by post,
after which an appointment at their health centre was made by telephone. A preventive
examination was made by physicians and nurses, and the person was given a report with
the result of the examination and convenient recommendations, a copy of which remained
at the health centre. This program followed the guidelines of the Spanish Society of Family
and Community Medicine (Villar Alvarez et al., 2003; Sepehri et al., 2014). The program
included screening for cardiovascular (hypertension, diabetes, dyslipidaemia, smoking,
obesity...) and gynaecologic (cytology, mammogram,. . . ) conditions and a vaccination
campaign (flu, tetanus and pneumococcal).
Study population
The study population comprised all persons who attended their health centre. The main
characteristics of these persons were: predominantly women, coexistence of CVRF, older
age and frequent visitors (Pedrera Carbonell et al., 2005).
Study design and participants
This observational, cross-sectional study analyzed a sample of nondiabetic persons
aged ≥40 years who had hypertension or were obese and who attended their health
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centre during the first six months of the preventive activities program of the Valencian
Community and who were willing to collaborate. A patient was considered to have
diabetes/hypertension if their physician had previously diagnosed these conditions with
codes 250/401 of ICD-9-CM. Obesity was defined as a body mass index (BMI)≥ 30 kg/m2.
Any patient who was diabetic or who did not have either of the two disorders (hypertension
or obesity) was excluded.
Variables
The main parameters constructed were:
(a) Poor BP control (≥140/90 mmHg) in patients with hypertension
(Chobanian et al., 2003).
(b) Class II obesity (BMI≥ 35 kg/m2) in obese patients (WHO, 1997).
(c) A SCORE≥ 5% (total cholesterol (TC) version) (Conroy et al., 2003). The SCORE is a
probabilistic equation to estimate the 10-year risk of cardiovascular death in persons
aged 40–65 years without prior CVD. The variables included in this model were: age,
gender, TC, systolic BP (SBP), and smoking. This parameter was defined for both
analyses (hypertension and obesity).
The following variables were also analyzed: gender, FBG group (<7.0 mmol/L,
5.6–7.0 mmol/L, <5.6 mmol/L) (Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus, 2003; Genuth et al., 2003), personal history of smoking or CVD
(coronary heart disease (CHD) or stroke), SBP and diastolic BP (DBP) (mmHg), TC
(mmol/L), age (years), and BMI (kg/m2). Based on the personal history of CVD, the
variable secondary cardiovascular prevention was defined as that patient who had already
experienced a cardiovascular event (CHD or stroke) prior to starting the study. A patient
was considered to be in primary cardiovascular prevention if they had no history of CVD at
the time of entering the study.
Measurements
The measurements of FBG and TC were made from first morning blood samples
taken after a minimum 8-h fast and using calibrated devices. The personal history of
diseases and smoking, the gender, and the age were ascertained at a patient interview
and corroborated with the medical history. The BP was measured in accordance with
current guidelines using well-calibrated semiautomated anaeroid—mercury—devices
under suitable conditions. The BMI was calculated from the weight and height, measured
with a calibrated scale and stadiometer after removing any objects that could affect the
weight and with no shoes. The SCORE was computed using all the variables required for its
calculation (Conroy et al., 2003).
Sample size
The sample included 5,347 patients with hypertension (of whom 3,003 fulfilled the criteria
for calculation of the SCORE) and 7,833 obese patients (SCORE in 5,827). We aimed to
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determine whether there existed dependence (Pearson X2 tests in a 3× 2 table) between
the FBG groups and the main parameters (control, class II obesity and high SCORE in
patients with hypertension or obesity). As the sample was collected prior to calculating the
sample size, we calculated the power of the contrast of the X2 with the sample (Chow, Wang
& Shao, 2007). Thus, we approximated the X2 value with the data of 1,500 hypertensive
and 1,500 obese patients selected randomly from the final sample. With these values and
using a significance level of 5%, we obtained a Pearson X2 contrast power>98% in all the
analyses done.
Statistical analysis
Absolute and relative frequencies are used to describe the qualitative variables, and means
and standard deviations for the quantitative variables. Multivariate logistic regression
models were used to estimate the adjusted odds ratio (ORs) in order to analyze the
relation between the main parameters (poor control of the BP, class II obesity and high
cardiovascular risk) and the other variables. For the analysis of the poor control of the BP
and class II obesity, the ORs were adjusted for gender, FBG group, smoking history, SBP,
DBP, TC, age, and BMI. In this analysis, we eliminated from the model those parameters
that had collinearity with the control of the BP and class II obesity (SBP and DBP for
hypertension, BMI for obesity). In the analysis of the high cardiovascular risk, the ORs
were adjusted for FBG group and BMI. The other variables were not used, given their
collinearity with the SCORE function (Conroy et al., 2003). The likelihood ratio test was
used to determine the fit of the models. All the analyses were done with a significance level
of 5% and the confidence intervals (CI) were calculated for the most relevant parameters.
The analyses were all done using IBM SPSS Statistics 19.
Ethical considerations
This study is based on an institutional agreement between the Conselleria de Sanitat and
Miguel Herna´ndez University, Elche (reference number: AVS-UV1.07X) authorized by
an Institutional Review Board (Universidad Miguel Herna´ndez de Elche-Conselleria de
Sanitat de la Generalitat Valenciana). The data were therefore analyzed in compliance with
current legislation on medical ethics. This institution played no role in data collection,
analysis or interpretation, nor in the publication of the final manuscript. Additionally, the
data were anonymized and encrypted, in accordance with the data protection law.
This population-based, non-interventional study (data from the Valencian Commu-
nity) used data from medical records and informed consent was not required for included
patients. The institutional agreement approved this consent procedure and ensured that
information access was restricted, it did not compromise the interests or welfare of any
patient, it minimized the risk of injury and its use was in line with current legislation.
RESULTS
Of a total of 5,347 patients with hypertension, 58.2% (95% CI [56.9–59.5]) had their BP
poorly controlled (Table 1). This poor control was significantly (p < 0.05) associated with:
male gender (OR= 1.26, 95% CI [1.12–1.42]), FBG group (≥7.0 mmol/L, OR= 1.43, 95%
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Table 1 Analysis of fasting blood glucose screening results in hypertensive patients at primary healthcare centres in the Valencian Community
(Spain), 2003–2004 data.
Variable Total
5,347
n(%)/x± s
Poor BP
control
3,113(58.2)
n(%)/x± sd
(Adj. OR) 95% CI
(Adj. OR)
Primary
prevention
≤65 years
3,003
n(%)/x± sd
High
cardiovascular
risk
278(9.3)
n(%)/x± sd
Adj. OR 95% CI
Adj. OR
Gender
Male 2,111(39.5) 1,288(61.0) 1.26d (1.12, 1.42) 1,115(37.1) 242(21.7) N/A N/A
Femalea 3,236(60.5) 1,825(56.4) 1,888(62.9) 36(1.9)
FBG groups
≥ 7.0 mmol/L 399(7.5) 264(66.2) 1.43 (1.15,1.79) 193(6.4) 23(11.9) 1.56 (0.97,2.51)
5.6–6.99 mmol/L 1,932(36.1) 1,201(62.2) 1.27 (1.13,1.43) 1,071(35.7) 113(10.6) 1.34 (1.03,1.75)
< 5.6 mmol/La 3,016(56.4) 1,648(54.6) d 1,739(57.9) 142(8.2) b
Personal history of
smoking
Yes 656(12.3) 381(58.1) 1.05 (0.88,1.25) 474(15.8) 110(23.2) N/A N/A
Noa 4,691(87.7) 2,732(58.2) 2,529(84.2) 168(6.6)
Secondary
prevention
Yes 673(12.6) 357(53.0) 0.73d (0.62,0.86) N/A N/A N/A N/A
Noa 4,674(87.6) 2,756(59.0)
SBP (mmHg) 138.5± 16.4 148.4± 13.2 N/A N/A 137.3± 16.3 152.2± 17.8 N/A N/A
DBP (mmHg) 82.4± 9.7 86.7± 9.1 N/A N/A 83.8± 9.8 88.4± 9.8 N/A N/A
TC (mmol/L) 5.5± 0.9 5.5± 0.9 1.10c (1.03,1.17) 5.5± 0.9 5.7± 0.9 N/A N/A
Age (Years) 61.8± 9.5 62.3± 9.3 1.02d (1.01,1.02) 55.9± 6.5 61.3± 3.8 N/A N/A
BMI (kg/m2) 29.9± 4.5 30.3± 4.6 1.05d (1.03,1.06) 30.0± 4.7 30.0± 4.1 0.99 (0.97,1.02)
Notes.
n(%), absolute frequency (relative frequency); x± sd, mean± standard deviation; BP, blood pressure; Adj. OR, adjusted odds ratio; CI, confidence interval; FBG, fasting
blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; BMI, body mass index; N/A, not applicable.
a Reference.
b 0.01 < p < 0.05.
c 0.001 < p < 0.01.
d p < 0.001.
Likelihood ratio test for poor control of the BP: X2 = 135.2 p < 0.001; primary prevention ≤65 years: X2 = 72.9 p < 0.001.
In the poor control analysis, OR were adjusted for gender, FBG groups, smoking, secondary prevention, TC, age, and BMI. SBP and DBP were not included in the
multivariate model due to collinearity with the control of the BP.
In primary prevention ≤ 65 years, OR were adjusted for FBG groups and BMI. Gender, smoking, SBP, TC and age were not included in the multivariate model due to
collinearity with the cardiovascular risk. DBP was not included because of the collinearity with the SBP. Secondary prevention was not included in the model because
the analysis was only in primary prevention patients.
CI [1.15-1.79]; 5.6–6.99 mmol/L, OR= 1.27, 95% CI [1.13–1.43];<5.6 mmol/L, OR= 1),
not being in secondary prevention (OR= 0.73, 95% CI [0.62–0.86]), high TC (OR= 1.10,
95% CI [1.03–1.17]), older age (OR= 1.02, 95% CI [1.01–1.02]), and BMI (OR= 1.05,
95% CI [1.03–1.06]). Figure 1A shows more clearly the relation between FBG level and
poor BP control; higher levels of FBG were associated with a greater likelihood of poor
control of the BP.
Table 1 also shows the analysis in the 3,003 patients who met the criteria for
calculation of the SCORE. The magnitude of a high cardiovascular risk was 9.3% (95%
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Figure 1 Predicted probability of high cardiovascular risk, poor control of hypertension and class
II obesity. 2003–2004 data. FBG, fasting blood glucose; BP, blood pressure. (A) Predicted probability
of poor blood pressure control in hypertense patients. (B) Predicted probability of high cardiovascular
risk in hypertense patients. (C) Predicted probability of class II obesity in obese patients. (D) Predicted
probability of high cardiovascular risk in obese patients.
CI [8.2–10.3%]), and it was significantly associated with the FBG group (≥7.0 mmol/L,
OR = 1.56, 95% CI [0.97–2.51]; 5.6–6.99 mmol/L, OR = 1.34, 95% CI [1.03–1.75];
<5.6 mmol/L, OR = 1). Figure 1B shows an increasing relation between FBG level and
a greater probability of having a high cardiovascular risk.
Of a total of 7,833 obese patients, 1,783 had a BMI ≥ 35 kg/m2 (22.8%, 95% CI
[21.8–23.7]) (Table 2). The factors significantly associated with class II obesity were:
female gender (OR= 0.46, 95% CI [0.41–0.52]), FBG group (≥7.0 mmol/L, OR= 2.11,
95% CI [1.73–2.57]; 5.6–6.99 mmol/L, OR = 1.22, 95% CI [1.08–1.36]; <5.6 mmol/L,
OR= 1), high SBP (OR= 1.01, 95% CI [1.01–1.02]), and younger age (OR= 0.98, 95% CI
[0.97–0.99]). As with hypertension, Fig. 1C also shows an increasing relation between FBG
levels and class II obesity.
The analysis of the 5,827 obese patients who had the criteria necessary to calculate the
SCORE showed a high SCORE in 6.2% (95% CI [5.6–6.8%]). The variables significantly
associated with this problem were the FBG levels (≥7.0 mmol/L, OR = 2.93, 95% CI
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Table 2 Analysis of fasting blood glucose screening results in obese patients at primary healthcare centres in the Valencian Community (Spain),
2003–2004 data.
Variable Total
7,833
n(%)/x± sd
Class II
obesity
1,783(22.8)
n(%)/x± sd
Adj.OR 95% CI
(Adj. OR)
Primary
prevention
≤ 65 years
5,827
n(%)/x± sd
High
cardiovascular
risk
360(6.2)
n(%)/x± sd
Adj. OR 95% CI
(Adj. OR)
Gender
Male 3,190(40.7) 513(16.1) 0.46d (0.41, 0.52) 2,365(40.6) 242(21.7) NA NA
Femalea 4,643(59.3) 1,270(27.4) 3,462(59.4) 36(1.9)
FBG groups
≥ 7.0 mmol/L 550(7.0) 187(34.0) 2.11 (1.73,2.57) 357(6.1) 23(11.9) 2.93 (2.02,4.25)
5.6–6.99 mmol/L 2,808(35.8) 659(23.5) 1.22 (1.08,1.36) 2,058(35.3) 113(10.6) 1.95 (1.55,2.44)
<5.6 mmol/La 4,475(57.1) 937(20.9) d 3,412(58.6) 142(8.2) d
Personal history of
smoking
Yes 1,380(17.6) 273(19.8) 0.92 (0.78,1.07) 1,222(21.0) 110(23.2) N/A N/A
Noa 6,453(82.4) 1,510(23.4) 4,605(79.0) 168(6.6)
Secondary
prevention
Yes 503(6.4) 118(23.5) 1.23b (0.98,1.53) N/A N/A N/A N/A
Noa 7,330(93.6) 1,665(22.7)
SBP (mmHg) 133.9± 17.0 136.0± 17.9 1.01d (1.01,1.02) 132.2± 16.8 150.3± 19.2 N/A N/A
DBP (mmHg) 81.4± 10.1 82.9± 10.6 N/A N/A 81.6± 10.2 87.5± 10.5 N/A N/A
TC (mmol/L) 5.5± 1.0 5.5± 0.9 0.95b (0.90,1.01) 5.5± 1.0 5.8± 1.0 N/A N/A
Age (Years) 56.7± 9.9 55.9± 9.7 0.98d (0.97,0.99) 52.6± 7.3 60.6± 4.3 N/A N/A
BMI (kg/m2) 33.3± 3.2 38.0± 3.0 N/A N/A 33.4± 3.3 32.9± 2.7 0.94c (0.98,0.98)
Notes.
n (%), absolute frequency (relative frequency); x± sd, mean ± standard deviation; Adj. OR, adjusted odds ratio; CI, confidence interval; FBG, fasting blood glucose;
SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; BMI, body mass index; N/A, not applicable.
a Reference.
b 0.05 < p < 0.1.
c 0.001 < p < 0.01.
d p < 0.001.
Likelihood ratio test for class II obesity: X2 = 290.0 p < 0.001; primary prevention ≤65 years: X2 = 56.8 p < 0.001.
In the poor control analysis, OR were adjusted for gender, FBG groups, smoking, secondary prevention, SBP, TC, and age. BMI was not included in the multivariate
model due to collinearity with the control of the obesity. DBP was not included because of the collinearity with the SBP.
In primary prevention ≤65 years, OR were adjusted for FBG groups and BMI. Gender, smoking, SBP, TC and age were not included in the multivariate model due to
collinearity with the cardiovascular risk. DBP was not included because of the collinearity with the SBP. Secondary prevention was not included in the model because
the analysis was only in primary prevention patients.
[2.02–4.25]; 5.6–6.99 mmol/L, OR= 1.95, 95% CI [1.55–2.44];<5.6 mmol/L, OR= 1). Of
note was the association between the increase in FBG level and a greater cardiovascular risk
(Fig. 1D).
DISCUSSION
The analysis of the patients with hypertension or obesity showed a direct relation between
the levels of FBG, and poor control of the BP and class II obesity, as well as with a greater
risk for death due to CVD. A search of the relevant literature produced just one study
evaluating the association in obese patients between cardiovascular risk (measured with
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a calibration of the Wilson scale of the Framingham Study) and inertia, considered to be
the absence of individualized advice to lose weight (Sepehri et al., 2014). The authors of
this study found the same association as us. Although other studies have related inertia
with poor control of CVRF, this inertia concerned persons who had already been diagnosed
with these CVRF (Okonofua et al., 2006). This indicates that there exists a lack of studies
addressing this topic.
When we started this study we expected to find that our patients who had no previous
diagnosis of diabetes would have a lower magnitude of altered FBG screening results and
that this would not be associated with a greater cardiovascular risk, poor BP control or
class II obesity. However, the results for this association were not expected, as all these
patients attended their health centre regularly. At these visits to control their CVRF, the
physicians ought to order a blood test to control the lipid and FBG levels in order to discard
the presence of dyslipidaemia and diabetes mellitus, respectively, as these CVRF usually
coexist in patients with hypertension and obesity (Pedrera Carbonell et al., 2005).
A possible explanation for detecting a greater cardiovascular risk in these hypertensive
or obese patients with no previous diagnosis of diabetes but with high FBG levels may
relate to the underestimation of the true cardiovascular risk, as healthcare professionals
are reported to use the risk functions recommended in the various clinical guidelines
inadequately (Banegas et al., 2006; Ma´rquez-Contreras et al., 2007).
Concerning the associations found between gender and the various outcomes, the men
had worse control of their hypertension, possibly because men generally attend their health
care centre less frequently for control of their CVRF, which could result in worse BP control
(Pedrera Carbonell et al., 2005). The women, however, were more likely to have class II
obesity. This, though, was expected and logical, as the prevalence of class II and III obesity
is higher in women than men in our region (Generalitat Valenciana: Conselleria de Sanitat,
2010b).
Healthcare policy should participate actively in the fight against diabetes mellitus via its
early detection and control, incorporating alarms in the electronic records systems when a
FBG measurement gives abnormal results or when a patient with one or more CVRF has
failed to have a FBG measurement for a certain number of months. Our results show the
need to integrate these healthcare policies in health centres to enable the early detection
of diabetes mellitus in the hypertensive or the obese patient. This will then encourage
physicians and nurses to attempt to control the disease thereby reducing the incidence of
CVD, as the most beneficial aspects of treatment of diabetes mellitus are seen during the
early stage of the disease (Schernthaner, 2010).
Strengths and limitations of the study
The main strength of this study is that it is the first to look at the possible cardiovascular
consequences of committing diagnostic inertia in patients with diabetes mellitus who
have a diagnosis of hypertension or obesity. The results therefore are novel. In addition,
the statistical power of the study is enhanced by the large sample size. This minimizes the
random error when drawing conclusions about a population attending their health centre.
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Moreover, the fact that all the health centres in the Valencian Community participated in
the study provides external validity. Furthermore, the contrast power used was over 98%,
when studies generally calculate their sample sizes from tables indicating an 80% or 90%
power.
The limitations are related to those found in any cross-sectional study measuring the
magnitude of a problem; that is, they are unable to produce any longitudinal or causal
findings. Concerning bias, the most important is selection bias, given the characteristics
of the study sample. This bias concerns the fact that it is the most motivated patients
who request a preventive check-up. For obvious reasons this cannot be changed, as each
person has a different degree of motivation. However, this does not affect the purpose of
the study, which was to assess the lack of detection of high FBG concentrations in patients
with no diagnosis of diabetes but who did have a diagnosis of hypertension or obesity. As
for measurement bias, all the teams were requested to use reliable devices to measure the
variables and to do the clinical interview correctly. Logically, this bias too is accepted in
this type of study. Finally, although we used 2003–2004 data, we have to take into account
that diagnostic inertia is a prevalent problem which was already detected in the 1980s
(Bell & Dippe, 1988); however, it was not named inertia, and even nowadays it is being
studied (Palazo´n-Bru et al., 2014). During these last decades the clinical guidelines have
been updated and certain cut-off control parameters have been modified, but diagnostic
inertia is still taking place.
CONCLUSIONS
This study provides useful information for clinical practice about the influence of the lack
of detection of high FBG concentrations in obese or hypertensive patients with no previous
diagnosis of diabetes mellitus; i.e., the possible repercussions of committing diagnostic
inertia in patients with diabetes. The FBG has a direct negative influence, associated with
a greater cardiovascular risk and worse control of BP and class II obesity. Nonetheless,
the results should be interpreted with caution until such time as other studies are able to
corroborate our findings.
The main learning point arising from this study is that we have to adopt a more
proactive attitude towards the diagnosis of diabetes mellitus in patients who are obese
or who have hypertension. This attitude should centre on the early detection of diabetes,
greater use of cardiovascular risk scales, and the incorporation of alert systems in the
electronic medical records of patients attending their healthcare professional to minimize
the problem and control the FBG in nondiabetic persons to detect the disease as early as
possible.
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